Medical Microinstruments Raises $125M in Series D Funding

MMI (Medical Microinstruments, Inc.), a Jacksonville, FL-based robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, has raised $125 million in a Series D financing round.

The round was led by existing investor BioStar Capital, with participation from new investors S3 Ventures, Angelini Ventures, and an undisclosed strategic corporate investor.

The company plans to use the funding to expand its business in the United States and other key markets and strengthen the clinical evidence supporting the wider use of robotic microsurgery.

What is Medical Microinstruments?

Medical Microinstruments develops robotic technology designed to help surgeons perform delicate procedures involving small blood vessels, nerves, and other soft tissues.

Read More:California-Based Voltus Secures $225M in Series D Funding

Its main product, the Symani Surgical System, combines miniature wristed surgical instruments with tremor-reduction and motion-scaling technologies. These features are designed to help surgeons perform precise movements during complex microsurgical procedures.

The system is intended for procedures such as cancer and trauma-related reconstructive surgery, lymphatic repair and nerve repair. These treatments can help patients recover function and improve their quality of life.

How Much Funding Has Medical Microinstruments Raised?

Medical Microinstruments has raised $125 million in its latest Series D funding round.

The announcement does not disclose the company's total funding raised to date or provide details of earlier funding rounds.

Who Invested in Medical Microinstruments’ Series D?

The $125 million Series D round was led by BioStar Capital, an existing investor in MMI.

Other participating investors include:

• S3 Ventures — a new investor
• Angelini Ventures — a new investor
• An undisclosed strategic corporate investor
• Existing investors who also participated in the round

Why the Funding Matters

MMI will use the funding to expand its commercial operations in the United States and key international markets. It also plans to strengthen the clinical evidence needed to support broader adoption of robotic microsurgery.

The investment comes as the company looks to make its Symani Surgical System available to more hospitals, surgeons, and patients. Building clinical evidence and supporting hospitals as they develop robotic microsurgery programs are part of its efforts to expand access to these procedures.

Who founded Medical Microinstruments?

Medical Microinstruments was founded in 2015 near Pisa, Italy. The funding announcement does not name the company's founders.

The company is currently based in Jacksonville, Florida, and develops robotic technology for soft-tissue open surgery and complex microsurgical procedures.

“We’ve proven there is demand for robotic microsurgery at leading institutions around the world. Now, our focus is translating that adoption into scale,” said Mark Toland, CEO of MMI. “This investment gives us the ability to expand our reach, accelerate adoption and continue advancing the platform through innovation in areas like energy instruments and digital surgery capabilities.”

“We’re excited to lead the oversubscribed round of funding. MMI represents the pinnacle of what we look for at BioStar: a transformational medical technology with the potential to revolutionize patient care and then some,” said Louie Cannon, MD, founder and senior managing director of BioStar Capital.

Market and Business Growth

MMI reports that approximately 50 Symani Surgical Systems have been installed worldwide. Surgeons have performed around 3,500 complex microsurgical procedures using the system.

The company is working with hospitals to develop robotic microsurgery programs and extend the use of its technology in reconstructive surgery, lymphatic repair, and nerve repair.

These installed systems and completed procedures provide a measure of the technology's current use. The announcement does not disclose revenue, customer growth, or other financial performance figures.

What Happens Next?

MMI plans to expand its business in the United States and key global markets while building further clinical evidence for robotic microsurgery.

The company will continue working with hospitals to develop microsurgery programs and broaden access to procedures that may help patients with complex conditions.

Read More:California-Based Ampersand Raises $15M in Series A Funding